UK Markets close in 1 hr 42 mins

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
86.05+1.02 (+1.20%)
As of 9:48AM EST. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 58.93B
Enterprise value 38.54B
Trailing P/E N/A
Forward P/E 1-134.45
PEG ratio (5-yr expected) 1-20.70
Price/sales (ttm)111.86
Price/book (mrq)19.54
Enterprise value/revenue 3106.98
Enterprise value/EBITDA 6-80.71

Trading information

Stock price history

Beta (5Y monthly) 1.40
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 392.60
52-week low 319.51
50-day moving average 383.03
200-day moving average 362.57

Share statistics

Avg vol (3-month) 3916.59k
Avg vol (10-day) 3827.28k
Shares outstanding 5103.79M
Float 100.46M
% held by insiders 12.60%
% held by institutions 167.06%
Shares short (11 Feb 2021) 45.02M
Short ratio (11 Feb 2021) 46.77
Short % of float (11 Feb 2021) 45.66%
Short % of shares outstanding (11 Feb 2021) 44.83%
Shares short (prior month 14 Jan 2021) 45.23M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 316 Nov 2011

Financial highlights

Fiscal year

Fiscal year ends 29 Sep 2020
Most-recent quarter (mrq)30 Dec 2020

Profitability

Profit margin -128.52%
Operating margin (ttm)-140.73%

Management effectiveness

Return on assets (ttm)-12.92%
Return on equity (ttm)-21.51%

Income statement

Revenue (ttm)79.84M
Revenue per share (ttm)0.78
Quarterly revenue growth (yoy)-27.70%
Gross profit (ttm)87.99M
EBITDA -105.83M
Net income avi to common (ttm)-102.61M
Diluted EPS (ttm)-1.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)305.33M
Total cash per share (mrq)2.94
Total debt (mrq)20.87M
Total debt/equity (mrq)4.59
Current ratio (mrq)12.90
Book value per share (mrq)4.40

Cash flow statement

Operating cash flow (ttm)-110.78M
Levered free cash flow (ttm)-90.66M